180 Life Sciences Corp.

Ivor Elrifi, CEO of Tiziana Life Sciences, bought 14,848 common shares at $1.65, raising his total holding to 193,848 shares. The purchase follows a 132% year-to-date price increase, although the stock recently fell 11%. Tiziana is developing intranasal Foralumab to treat multiple sclerosis; an expanded-access program showed stabilization or improvement in ten patients, and a randomized phase-2a study is ongoing. The company has a market capitalization of around $180 million, a negative EBITDA of $15.8 million, and is, in consensus, by analysts as » More on de.investing.com

ETHZilla said it will begin an up to $250 million stock repurchase plan immediately and reported it holds 102,237 Ether and about $215 million in USD stablecoins. The company, formerly 180 Life Sciences (ticker ATNF) and backed by Peter Thiel, shifted its focus to accumulating Ether and said the buyback underscores its commitment to shareholder value. Shares jumped about 9% on the announcement and have nearly doubled this year. » More on finance.yahoo.com

Shares of 180 Life Sciences Corp surged after a filing showed Peter Thiel's Founders Fund Growth Management acquired a 7.5% stake in the company, which has transitioned to an Ethereum-focused digital asset treasury (DAT) model and holds significant ether and cash reserves. The stock spike followed the disclosure of the firm's crypto holdings and contrasts with other crypto-accumulating firms that use leverage, while BitMine also raised its equity program to finance more Ethereum purchases. The move was reported alongside commentary on convertible-debt strategies used by peers and the potential risks of leveraged accumulation. » More on finance.yahoo.com